Friday, May 20, 2016 9:11:17 PM
they still make their strike prices regardless of where the share price trades
why do you think they call it death spiral financing
and if the volume diminishes, they'll put a pump & dump together
and you'll get 2 or 3 days worth of activity
separated by months of more conversions, RS's and AS increases
AMBS's business model failed gloriously
they have failed to license anything noteworthy
they have failed to get CLIA for their AMDX products
they have no AFIRM grant funding to run ESS test trials with
no $7.45-Mil. Grow NJ Assistance Tax Credit on the DioGenix deal
they have no near term assets that can produce any kind of revenue
Eltopra Ph 2 studies will require more testing
MANF is light years away from any revenue whatsoever
SeraPro, NuroPro, PhenoGuard, Georgetown Assays can't generate revenue
and they went out on a $40-Mil. reckless sending spree on credit
and didn't buy anything that was revenue producing whatsoever
bottom line - their broke
and have now been taken to the cleaners by the toxic lenders
and as a result, lost majority control of the company
Gerald hyped the company for years
and now his name along with the company's is permanently corrosive
sad but true...
AJMHO
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM